Health authorities move to protect farmworkers and other high-risk groups after recent outbreaks
Independent experts conclude unanimously that the experimental treatment is effective
Vaccine maker to seek approval for jab as it tries to diversify product pipeline
Pharma group believes successful medicines from its clinical trials could generate $20bn in revenue by 2030
Two developers of drugs for inflammatory diseases are latest to disregard poor performance of newly listed companies
Launch highlights growth of venture philanthropy to boost search for treatments and cures
As incidence rises, breakthroughs in oncology show the value of research funding
Both OZEM and THNR offer very concentrated bets on a fast-moving market
Brent Wisner, who won billions of dollars against Bayer, has received a big boost in Zantac cancer case
Non-binding vote on psychedelic drug will carry weight with FDA in blow to pharmaceutical developers
Litigation over Zantac is only one of several doubts the UK pharma group needs to overcome
Ruling means plaintiffs can present evidence alleging link between heartburn drug and cancer
The deal is expected to be one of Europe’s largest this year as EU IPO market shows signs of recovery
Judge rules experts’ evidence admissible, leaving route open for 72,000 cancer sufferers to bring cases
US decision hands biotech group its first regulatory blessing since its blockbuster Covid-19 jab
Funding would help to bolster stockpile as CDC reports third dairy worker infected
People with cystic fibrosis, epilepsy and diabetes among those struggling with medicine shortages
US group hopes EyeBio will refill its pipeline with treatments targeting causes of blindness
Merck, GSK and AstraZeneca have all signed deals
US drugmaker races to scale up ingredient production to meet demand for Mounjaro and Zepbound jabs
As Covid revenues slump, technology developed to fight the pandemic is having some success combating this disease
Fears of growing outbreak drive revival in vaccine group stocks which have been out of favour since pandemic ended
Anglo-Swedish drugmaker targets $80bn in revenue by 2030
Serum Institute of India says it is losing money on each dose it supplies for historic first mass vaccination campaign
Brian Langstaff’s long-awaited report found failures by government departments and various parts of NHS
UK Edition